{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T16:20:08Z","timestamp":1778602808070,"version":"3.51.4"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.clim.2018.12.015","type":"journal-article","created":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T14:42:17Z","timestamp":1544798537000},"page":"54-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["IgE blockade in autoimmunity: Omalizumab induced remission of bullous pemphigoid"],"prefix":"10.1016","volume":"198","author":[{"given":"Talia","family":"James","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam","family":"Salman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brittany","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Bundell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4501-0443","authenticated-orcid":false,"given":"Gavin","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Nolan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mina","family":"John","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2018.12.015_bb0005","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1111\/jdv.13758","article-title":"Megahed M successful treatment of bullous pemphigoid with omalizumab as corticosteroid-sparing agent: report of two cases and review of literature","volume":"30","author":"Balakirski","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.clim.2018.12.015_bb0010","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jaad.2014.04.053","article-title":"Omalizumab therapy for bullous pemphigoid","volume":"71","author":"Yu","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.clim.2018.12.015_bb0015","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.clim.2012.02.003","article-title":"IgE recognition of bullous pemphigoid (BP)180 and BP230 in BP patients and elderly individuals with pruritic dermatoses","volume":"143","author":"Fania","year":"2012","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2018.12.015_bb0020","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1046\/j.1523-1747.2003.12146.x","article-title":"Identification of a potential effector function for IgE autoantibodies in the organ-specific autoimmune disease bullous pemphigoid","volume":"120","author":"Dimson","year":"2003","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.clim.2018.12.015_bb0025","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s12026-014-8547-7","article-title":"Unraveling the significance of IgE autoantibodies in organ-specific autoimmunity: lessons learned from bullous pemphigoid","volume":"59","author":"Messingham","year":"2014","journal-title":"Immunol. Res."},{"key":"10.1016\/j.clim.2018.12.015_bb0030","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/j.1365-2133.2011.10481.x","article-title":"Detection of linear IgE deposits in bullous pemphigoid and mucous membrane pemphigoid: a useful clue for diagnosis","volume":"165","author":"Yayli","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.clim.2018.12.015_bb0035","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2340\/00015555-2101","article-title":"Wozniak K enzyme-linked immunoassay index for Anti-NC16a IgG and IgE Auto-antibodies correlates with severity and activity of bullous pemphigoid","volume":"96","author":"Kalowska","year":"2016","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.clim.2018.12.015_bb0040","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1038\/sj.jid.5700958","article-title":"Giudice GJ a pathogenic role for IgE in autoimmunity: bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu\/nu mice","volume":"127","author":"Fairley","year":"2007","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.clim.2018.12.015_bb0045","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/sj.jid.5700681","article-title":"IgE basement membrane zone antibodies induce eosinophil infiltration and histological blisters in engrafted human skin on SCID mice","volume":"127","author":"Zone","year":"2007","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.clim.2018.12.015_bb0050","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jid.2017.11.031","article-title":"Eosinophils Mediate Tissue Injury in the Autoimmune Skin Disease Bullous Pemphigoid","volume":"138","author":"Lin","year":"2018","journal-title":"J. Invest. Dermatol."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661618305400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661618305400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T22:47:58Z","timestamp":1548974878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661618305400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":10,"alternative-id":["S1521661618305400"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2018.12.015","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IgE blockade in autoimmunity: Omalizumab induced remission of bullous pemphigoid","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2018.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2018 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}